FSD Pharma

HomeFSD Pharma

FSD.CN

Recent Headlines

FSD Pharma Announces Phase 2 Clinical Trial IND Filing With The FDA to Treat Patients With COVID-19
Source: FSD Pharma Published on 2020-08-31
FSD Pharma Announces Phase 2 Clinical Trial IND Filing with the FDA to Treat Patients with COVID-19
Source: FSD Pharma Published on 2020-08-31
HUGE.CN: FSD Pharma’s FSD’s Phase 1 Safety and Tolerability Study of FSD201 was Successfully Completed. Pre-IND Meeting Requested for the Treatment of COVID-19 Patients Filed with FDA.
Source: FSD Pharma Published on 2020-08-20
FSD Pharma Reports Second Quarter 2020 Financial Results
Source: FSD Pharma Published on 2020-08-07
FSD Pharma Inc. Announces Closing of US$10 Million Registered Direct Offering to Institutional Investors
Source: FSD Pharma Published on 2020-08-06
FSD Pharma Inc., Developing its PEA Compound to Treat COVID-19, CEO Clip Video
Source: FSD Pharma Published on 2020-07-31
FSD Pharma Inc. Announces US$10 Million Registered Direct Offering
Source: FSD Pharma Published on 2020-07-31
FSD Pharma Announces Decision to Surrender Health Canada Licenses for Subsidiary FV Pharma Inc.
Source: FSD Pharma Published on 2020-07-30
FSD Pharma Announces US$20M At-The-Market Offering
Source: FSD Pharma Published on 2020-07-13
InvestmentPitch Media Video Discusses FSD Pharma's Report of Favorable Topline Results from Phase 1 First-in-Human Safety and Tolerability Study of Ultra-micronized PEA - Video Available on Investmentpitch.com
Source: FSD Pharma Published on 2020-06-23
FSD Pharma Reports Favorable Topline Results from Phase 1 First-in-Human Safety and Tolerability Study of Ultramicronized PEA
Source: FSD Pharma Published on 2020-06-22
FSD Pharma Announces Closing of C$10.125 Million Private Placement to Institutional Investors
Source: FSD Pharma Published on 2020-06-09
HUGE.CN: FSD Pharma is conducting Phase 1 clinical trial of FSD-201 for inflammation and has FDA approval for a Phase 2a clinical trial design for the treatment of COVID-19 patients
Source: FSD Pharma Published on 2020-06-09
FSD Pharma Inc. Announces C$10.125 Million Private Placement
Source: FSD Pharma Published on 2020-06-04
Covid Report: Small Biotech Triples On Plans To Test A Coronavirus Drug
Source: FSD Pharma Published on 2020-06-03
/C O R R E C T I O N -- Investment Industry Regulatory Organization of Canada (IIROC) - Halts/Resumptions/
Source: FSD Pharma Published on 2020-06-03
IIROC Trading Halt - HUGE
Source: FSD Pharma Published on 2020-06-03
FSD Pharma Receives U.S. FDA Approval to Design a Phase 2a Clinical Trial to Treat Patients with Suspected or Confirmed COVID-19 Diagnosis
Source: FSD Pharma Published on 2020-06-03
FSD Pharma Receives U.S. FDA Approval to design a Phase 2a Clinical Trial to Treat Patients with Suspected or Confirmed COVID-19 Diagnosis
Source: FSD Pharma Published on 2020-06-03
FSD Pharma Monetizes Non-Core Asset with Sale of Partial Equity Stake in Pharmadrug Inc.
Source: FSD Pharma Published on 2020-05-21
FSD Pharma Monetizes Non-Core Asset With Sale of Partial Equity Stake in Pharmadrug Inc.
Source: FSD Pharma Published on 2020-05-21
FSD Pharma Reports First Quarter 2020 Financial Results
Source: FSD Pharma Published on 2020-05-14
FSD Pharma Reports First Quarter 2020 Financial Results
Source: FSD Pharma Published on 2020-05-14
FSD Pharma Takes Steps to Mitigate the Impact of COVID-19 on its Cannabis Production Facility in Cobourg, Ontario
Source: FSD Pharma Published on 2020-03-23
InvestmentPitch Media Video Discusses FSD Pharma's Initiation of Phase 1 In-Human Safety & Tolerability Study of Dosing Ultra Micro-PEA for Targeting CB2 Receptors at Alfred Hospital in Australia - Video Available on Investmentpitch.com
Source: FSD Pharma Published on 2020-03-10
FSD Pharma Begins Phase 1 In-human Safety and Tolerability Study of Ultra Micro-Palmitolylethanolamide (PEA)
Source: FSD Pharma Published on 2020-03-09
FSD Pharma Begins Phase 1 In-human Safety and Tolerability Study of Ultra Micro-Palmitolylethanolamide (PEA)
Source: FSD Pharma Published on 2020-03-09
FSD Pharma Inc., Worldwide License of Natural Fatty Acid, CEO Clip Video
Source: FSD Pharma Published on 2020-03-06
FSD Pharma to Ring the Opening Bell of the Canadian Securities Exchange On Friday, March 6, 2020
Source: FSD Pharma Published on 2020-03-04
FSD Pharma to Ring the Opening Bell of the Canadian Securities Exchange on Friday, March 6, 2020
Source: FSD Pharma Published on 2020-03-04
InvestmentPitch Media Video Discusses FSD Pharma's Sale of its 12% Interest in Cannara Biotech Generating 670% Return and $7.7 million in Proceeds - Video Available on Investmentpitch.com
Source: FSD Pharma Published on 2020-02-24
FSD Pharma Generates $7.7 Million in Proceeds and 670% Return on Investment through Sale of Interest in Cannara Biotech
Source: FSD Pharma Published on 2020-02-20
FSD Pharma CEO, Dr. Raza Bokhari, Discusses 2020 Goals with The Stock Day Podcast
Source: FSD Pharma Published on 2020-02-11
FSD Pharma Chairman & CEO to Present at 22nd Annual BIO CEO & Investor Conference in NYC
Source: FSD Pharma Published on 2020-02-05
FSD Pharma Chairman & CEO to Present at 22nd Annual BIO CEO & Investor Conference in NYC
Source: FSD Pharma Published on 2020-02-05
FSD Pharma and Solarvest Enhance Commitment to CBD Research Project
Source: FSD Pharma Published on 2020-02-04
FSD Pharma and Solarvest Enhance Commitment to CBD Research Project
Source: FSD Pharma Published on 2020-02-04
Seasoned Healthcare Executive and Academic Luminary Larry Kaiser, MD, Joins FSD Pharma Board of Directors
Source: FSD Pharma Published on 2020-01-22
Seasoned Healthcare Executive and Academic Luminary Larry Kaiser, MD, Joins FSD Pharma Board of Directors
Source: FSD Pharma Published on 2020-01-22
FSD Pharma to Ring Nasdaq Opening Bell on Wednesday, January 22, 2020
Source: FSD Pharma Published on 2020-01-17
InvestmentPitch Media Video Discusses FSD Pharma's New Listing on the Nasdaq Capital Market and Upcoming Biotech and Healthcare Conferences - Video Available on Investmentpitch.com
Source: FSD Pharma Published on 2020-01-10
FSD Pharma to Commence Trading on Nasdaq Capital Market Under Symbol ‘HUGE’
Source: FSD Pharma Published on 2020-01-09
FSD Pharma to Commence Trading on Nasdaq Capital Market Under Symbol 'HUGE'
Source: FSD Pharma Published on 2020-01-09
FSD Pharma to Begin Trading on the NASDAQ Capital Market Under Symbol ‘HUGE’ on January 9, 2020
Source: FSD Pharma Published on 2020-01-06
FSD Pharma to Begin Trading on the NASDAQ Capital Market Under Symbol 'HUGE' on January 9, 2020
Source: FSD Pharma Published on 2020-01-06
FSD Pharma Strengthens Management Team
Source: FSD Pharma Published on 2020-01-02
FSD Pharma Strengthens Management Team
Source: FSD Pharma Published on 2020-01-02
InvestmentPitch Media Video Discusses FSD Pharma's Approval of Listing Application for Nasdaq Capital Market with trading Anticipated to Begin Shortly - Video Available on Investmentpitch.com
Source: FSD Pharma Published on 2019-12-17
IIROC Trade Resumption - HUGE
Source: FSD Pharma Published on 2019-12-16
FSD Pharma Receives Approval to List Its Shares on Nasdaq
Source: FSD Pharma Published on 2019-12-16

Login
Register